FilingReader Intelligence
Hester Biosciences consolidated profit surges 131% despite standalone decline
August 1, 2025 at 06:59 AM UTC•By FilingReader AI
Hester Biosciences reported mixed Q1 FY26 results with standalone product sales down 14% and profit declining 7%.
However, consolidated net profit surged 131% to INR 172.96 million, driven by Hester Africa's turnaround. Consolidated divisional product sales grew 2% to INR 840.89 million.
The Animal Healthcare division faced a 33% sales decline due to program delays.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
BSE:HESTERBIO•Bombay Stock Exchange
News Alerts
Get instant email alerts when Hester Biosciences publishes news
Free account required • Unsubscribe anytime